Nuevos fármacos para el tratamiento de la hipercolesterolemia
Statins are the preferred treatment for hypercholesterolemia and several studies have demonstrated their long-term safety and efficacy in reducing cardiovascular morbidity and mortality. However, in some cases of severe hypercholesterolemia such as homozygous and heterozygous familial hypercholesterolemia or statin intolerant patients, statins can be less efficient. In recent years, new lipid-lowering agents with novel mechanisms of action have been developed to reduce LDL-cholesterol in patients with severe hypercholesterolemia, associated or not to conventional lipid-lowering therapy. These therapies include microsomal transfer protein inhibitor (Lomitapide), antisense oligonucleotide to Apo B100 (Mipomersen) and monoclonal antibodies against Proprotein convertase subtilisin/kexin type 9 (PCSK9). Different studies have shown the great effectiveness of these new therapies. Short-term studies confirmed their adequate security profile, especially in patients with homozygous familiar hypercholesterolemia or severe hypercholesterolemia. Some of these agents have been also tested in statin-intolerant patients. However, long-term studies are needed to evaluate their safety, effectiveness and impact on cardiovascular risk reduction.
Main Authors: | , , |
---|---|
Format: | Digital revista |
Language: | Spanish / Castilian |
Published: |
Sociedad Médica de Santiago
2014
|
Online Access: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000700008 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0034-98872014000700008 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0034-988720140007000082014-12-10Nuevos fármacos para el tratamiento de la hipercolesterolemiaCuevas,AdaFarías,María MagdalenaAlonso,Rodrigo Anticholesteremic agents Hypercholesterolemia, familial combined Lipido-lowering therapy Lomitapide Mipomersen Statins are the preferred treatment for hypercholesterolemia and several studies have demonstrated their long-term safety and efficacy in reducing cardiovascular morbidity and mortality. However, in some cases of severe hypercholesterolemia such as homozygous and heterozygous familial hypercholesterolemia or statin intolerant patients, statins can be less efficient. In recent years, new lipid-lowering agents with novel mechanisms of action have been developed to reduce LDL-cholesterol in patients with severe hypercholesterolemia, associated or not to conventional lipid-lowering therapy. These therapies include microsomal transfer protein inhibitor (Lomitapide), antisense oligonucleotide to Apo B100 (Mipomersen) and monoclonal antibodies against Proprotein convertase subtilisin/kexin type 9 (PCSK9). Different studies have shown the great effectiveness of these new therapies. Short-term studies confirmed their adequate security profile, especially in patients with homozygous familiar hypercholesterolemia or severe hypercholesterolemia. Some of these agents have been also tested in statin-intolerant patients. However, long-term studies are needed to evaluate their safety, effectiveness and impact on cardiovascular risk reduction.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.142 n.7 20142014-07-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000700008es10.4067/S0034-98872014000700008 |
institution |
SCIELO |
collection |
OJS |
country |
Chile |
countrycode |
CL |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-cl |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
Spanish / Castilian |
format |
Digital |
author |
Cuevas,Ada Farías,María Magdalena Alonso,Rodrigo |
spellingShingle |
Cuevas,Ada Farías,María Magdalena Alonso,Rodrigo Nuevos fármacos para el tratamiento de la hipercolesterolemia |
author_facet |
Cuevas,Ada Farías,María Magdalena Alonso,Rodrigo |
author_sort |
Cuevas,Ada |
title |
Nuevos fármacos para el tratamiento de la hipercolesterolemia |
title_short |
Nuevos fármacos para el tratamiento de la hipercolesterolemia |
title_full |
Nuevos fármacos para el tratamiento de la hipercolesterolemia |
title_fullStr |
Nuevos fármacos para el tratamiento de la hipercolesterolemia |
title_full_unstemmed |
Nuevos fármacos para el tratamiento de la hipercolesterolemia |
title_sort |
nuevos fármacos para el tratamiento de la hipercolesterolemia |
description |
Statins are the preferred treatment for hypercholesterolemia and several studies have demonstrated their long-term safety and efficacy in reducing cardiovascular morbidity and mortality. However, in some cases of severe hypercholesterolemia such as homozygous and heterozygous familial hypercholesterolemia or statin intolerant patients, statins can be less efficient. In recent years, new lipid-lowering agents with novel mechanisms of action have been developed to reduce LDL-cholesterol in patients with severe hypercholesterolemia, associated or not to conventional lipid-lowering therapy. These therapies include microsomal transfer protein inhibitor (Lomitapide), antisense oligonucleotide to Apo B100 (Mipomersen) and monoclonal antibodies against Proprotein convertase subtilisin/kexin type 9 (PCSK9). Different studies have shown the great effectiveness of these new therapies. Short-term studies confirmed their adequate security profile, especially in patients with homozygous familiar hypercholesterolemia or severe hypercholesterolemia. Some of these agents have been also tested in statin-intolerant patients. However, long-term studies are needed to evaluate their safety, effectiveness and impact on cardiovascular risk reduction. |
publisher |
Sociedad Médica de Santiago |
publishDate |
2014 |
url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000700008 |
work_keys_str_mv |
AT cuevasada nuevosfarmacosparaeltratamientodelahipercolesterolemia AT fariasmariamagdalena nuevosfarmacosparaeltratamientodelahipercolesterolemia AT alonsorodrigo nuevosfarmacosparaeltratamientodelahipercolesterolemia |
_version_ |
1755988461596180480 |